Comparative Pharmacology
Head-to-head clinical analysis: THIOTHIXENE HYDROCHLORIDE INTENSOL versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIOTHIXENE HYDROCHLORIDE INTENSOL versus THORAZINE.
THIOTHIXENE HYDROCHLORIDE INTENSOL vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has affinity for serotonin 5-HT2, histamine H1, and alpha-1 adrenergic receptors, contributing to its therapeutic and adverse effects.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Initial: 2 mg orally three times daily. Maintenance: 15-30 mg orally daily in divided doses. Maximum: 60 mg/day.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life ranges from 26 to 36 hours in healthy adults, allowing for once-daily dosing in maintenance therapy. In chronic use, the half-life may be prolonged due to accumulation.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily renal and biliary; about 50-60% of a single dose is excreted in the urine as metabolites and unchanged drug within 48 hours, with approximately 30-40% eliminated in feces via biliary secretion. Less than 1% of the parent drug is excreted unchanged in urine.
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category C
Category C
Typical Antipsychotic
Typical Antipsychotic